Upcoming first-line chemotherapy for HER2-negative gastric cancer in Japan: which patients benefit from immunotherapy?

被引：4
|
作者：
Takahari, Daisuke [1 ]
Chin, Keisho [1 ]
Yamaguchi, Kensei [1 ]
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol, Tokyo, Japan
来源：
FUTURE ONCOLOGY | 2020年 / 16卷 / 24期
关键词：
first-line chemotherapy; gastric cancer; pembrolizumab monotherapy; TAS-118 plus oxaliplatin; SOL; DOUBLE-BLIND; PHASE-III; CISPLATIN; NIVOLUMAB; S-1;
D O I：
10.2217/fon-2020-0421
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1797 / 1799
页数：3
相关论文
共 50 条
  • [1] Comparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Cancer
    Urakci, Zuhat
    Ebinc, Senar
    Tunc, Sezai
    Kalkan, Ziya
    Oruc, Zeynep
    Kucukoner, Mehmet
    Kaplan, Muhammet Ali
    Isikdogan, Abdurrahman
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (05)
  • [2] A RETROSPECTIVE ANALYSIS OF FIRST-LINE TREATMENT IN HER2-POSITIVE AND HER2-NEGATIVE ADVANCED GASTRIC CANCER
    Onodera, K.
    Kawakami, K.
    Yukisawa, S.
    Warita, E.
    Yamanaka, Y.
    ANNALS OF ONCOLOGY, 2013, 24 : 68 - 68
  • [3] Endocrine therapy or chemotherapy as first-line therapy in hormone receptorepositive HER2-negative metastatic breast cancer patients
    Jacquet, E.
    Lardy-Cleaud, A.
    Pistilli, B.
    Franck, S.
    Cottu, P.
    Delaloge, S.
    Debled, M.
    Vanlemmens, L.
    Leheurteur, M.
    Guizard, A. V.
    Laborde, L.
    Uwer, L.
    Jacot, W.
    Berchery, D.
    Desmoulins, I.
    Ferrero, J. M.
    Perrocheau, G.
    Courtinard, C.
    Brain, E.
    Chabaud, S.
    Robain, M.
    Bachelot, T.
    EUROPEAN JOURNAL OF CANCER, 2018, 95 : 93 - 101
  • [4] Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice
    Laterza, Maria Maddalena
    Pompella, Luca
    Petrillo, Angelica
    Tirino, Giuseppe
    Pappalardo, Annalisa
    Orditura, Michele
    Troiani, Teresa
    Ciardiello, Fortunato
    Di Martino, Natale
    De Vita, Ferdinando
    MEDICAL ONCOLOGY, 2017, 34 (11)
  • [5] Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice
    Maria Maddalena Laterza
    Luca Pompella
    Angelica Petrillo
    Giuseppe Tirino
    Annalisa Pappalardo
    Michele Orditura
    Teresa Troiani
    Fortunato Ciardiello
    Natale Di Martino
    Ferdinando De Vita
    Medical Oncology, 2017, 34
  • [6] First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients
    Miles, D. W.
    Dieras, V.
    Cortes, J.
    Duenne, A. -A.
    Yi, J.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2013, 24 (11) : 2773 - 2780
  • [7] Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric cancer in real-world patients: Updated analysis.
    Shimozaki, Keitaro
    Fukuda, Koshiro
    Ooki, Akira
    Nakayama, Izuma
    Yoshino, Koichiro
    Udagawa, Shohei
    Fukuoka, Shota
    Osumi, Hiroki
    Ogura, Mariko
    Wakatsuki, Takeru
    Takahari, Daisuke
    Shinozaki, Eiji
    Chin, Keisho
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 341 - 341
  • [8] Maintenance bevacizumab after first-line treatment in HER2-negative metastatic breast cancer patients
    Fabi, A.
    Russillo, M.
    Metro, G.
    Papaldo, P.
    Nistico, C.
    Ferretti, G.
    Cuppone, F.
    D'Auria, G.
    Giannarelli, D.
    Cognetti, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
    Tamura, Kenji
    Inoue, Kenichi
    Masuda, Norikazu
    Takao, Shintaro
    Kashiwaba, Masahiro
    Tokuda, Yutaka
    Iwata, Hiroji
    Yamamoto, Naohito
    Aogi, Kenjiro
    Saeki, Toshiaki
    Nakayama, Takahiro
    Sato, Nobuaki
    Toyama, Tatsuya
    Ishida, Takanori
    Arioka, Hitoshi
    Saito, Mitsue
    Ohno, Shinji
    Yamauchi, Hideko
    Yamada, Kimito
    Watanabe, Junichiro
    Ishiguro, Hiroshi
    Fujiwara, Yasuhiro
    CANCER SCIENCE, 2017, 108 (05): : 987 - 994
  • [10] Modified Docetaxel and Cisplatin in Combination with Capecitabine (DCX) as a First-Line Treatment in HER2-Negative Advanced Gastric Cancer
    Bilici, Ahmet
    Selcukbiricik, Fatih
    Demir, Nazan
    Ustaalioglu, Bala Basak Oven
    Dikilitas, Mustafa
    Yildiz, Ozcan
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (20) : 8661 - 8666
12345